^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MAGE A3 TCR

    i
    Other names: MAGE A3 TCR, anti-MAGE A3 HLA-A-01-restricted TCR, anti-MAGE-A3-DP4-TCR, anti-MAGE-A3-TCR
    Associations

    News

    Trials
    Company:
    Gilead, National Cancer Institute
    Drug class:
    TCR modulator, MAGE-A3 modulator
    Related drugs:
    Associations

    News

    Trials
    almost4years
    T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive (clinicaltrials.gov)
    P1/2, N=21, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Mar 2021 | Trial primary completion date: Dec 2023 --> Mar 2021
    Clinical • Trial completion • Trial completion date • Trial primary completion date
    |
    GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) • MAGEA3 (MAGE Family Member A3)
    |
    fludarabine IV • Proleukin (aldesleukin) • MAGE A3 TCR • cyclophosphamide intravenous